Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADRONASDAQ:BLCMNASDAQ:NBSENASDAQ:OASMNASDAQ:OTIC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsNBSENeuBase Therapeutics$0.43-0.1%$0.71$0.39▼$4.80$1.62M0.83209,079 shs36,158 shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/AOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%-29.13%-82.11%NBSENeuBase Therapeutics+1.07%+3.49%-58.80%-30.76%-88.21%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADROAduro BiotechN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro BiotechN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00BLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33NBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/AOASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/ABLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ANBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91BLCMBellicum PharmaceuticalsN/A3.043.04NBSENeuBase TherapeuticsN/A2.872.87OASMOasmia Pharmaceutical AB (publ)N/A0.800.73OTICOtonomyN/A1.741.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%BLCMBellicum Pharmaceuticals4.93%NBSENeuBase Therapeutics12.37%OASMOasmia Pharmaceutical AB (publ)0.11%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%BLCMBellicum Pharmaceuticals10.30%NBSENeuBase Therapeutics13.90%OASMOasmia Pharmaceutical AB (publ)N/AOTICOtonomy1.09%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableNBSENeuBase Therapeutics373.75 million3.23 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableOTICOtonomy5168.53 million67.78 millionOptionableADRO, OASM, BLCM, OTIC, and NBSE HeadlinesSourceHeadlineAllergic Contact Dermatitis and Topical Antibioticsmedscape.com - September 10 at 4:13 PMHearing Loss in Adultsnejm.org - August 21 at 11:30 PMResearch Publicationsslu.edu - August 4 at 7:44 PMManagement of Pediatric Otitis Mediamedscape.com - May 11 at 11:26 PMHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRnews.google.com - May 8 at 10:11 AMAlluvial Capital Management Q1 2023 Letter To Partners - Seeking Alphanews.google.com - April 28 at 7:44 AMVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital Journalnews.google.com - April 27 at 9:58 AMHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRnews.google.com - April 25 at 4:57 PMENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital Journalnews.google.com - April 24 at 7:52 AMHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital Journalnews.google.com - April 11 at 10:37 PMENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital Journalnews.google.com - April 10 at 7:51 AM[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journalnews.google.com - April 10 at 7:51 AMHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital Journalnews.google.com - April 3 at 7:09 PMHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints Newsnews.google.com - March 30 at 1:22 PMAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswirenews.google.com - March 29 at 8:47 PMSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpacenews.google.com - March 29 at 10:46 AMOtic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029| Pediapharm Novus Therap - openPRnews.google.com - March 27 at 9:52 AMHearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital Journalnews.google.com - March 23 at 9:50 AMHearing Loss Disease Treatment Market 2023 key developmental ... - openPRnews.google.com - March 22 at 6:46 PMHearing Loss Disease Treatment Market 2023 key developmental strategies implemented by the key players till 20 - openPRnews.google.com - March 21 at 9:36 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetUiPath Cuts Q1 and Raises Full Year GuidanceMarch 26, 2024 7:41 AMView UiPath Cuts Q1 and Raises Full Year Guidance3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsAduro BiotechNASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Bellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.